Výsledky vyhledávání - "S. S. Taflan"

POS0816 DRUG SURVIVAL OF INFLIXIMAB IN BEHÇET’S SYNDROME PATIENTS WITH DIFFERENT TYPES OF INVOLVEMENT

Autor: S. N. Esatoglu, B. Tukek, S. S. Taflan, Y. Ozyazgan, D. Ucar, V. Hamuryudan, Y. Ozguler, E. Seyahi, M. Melikoglu, U. Uygunoglu, A. Siva, Z. Kutlubay, I. Fresko, S. Yurdakul, H. Yazici, G. Hatemi

Publikováno v: Annals of the Rheumatic Diseases. 81:697.2-698

BackgroundInfliximab (IFX) is an effective therapeutic option in the management of severe and refractory manifestations of Behçet’s syndrome (BS).ObjectivesWe aimed to evaluate long term drug survival of IFX in a large cohort of BS patients.Method

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ea4007c3961b6cf075baf3e612954184
https://doi.org/10.1136/annrheumdis-2022-eular.3951

Zobrazit plný text záznamu

POS0814 OUTCOME OF VASCULAR INVOLVEMENT OF BEHÇET’S SYNDROME TREATED WITH INFLIXIMAB: A RETROSPECTIVE COHORT STUDY

Autor: G. Hatemi, B. Tukek, S. N. Esatoglu, Y. Ozguler, S. S. Taflan, M. Melikoglu, S. Ugurlu, I. Fresko, Z. Kutlubay, S. Yurdakul, H. Yazici, V. Hamuryudan

Publikováno v: Annals of the Rheumatic Diseases. 81:696.2-697

BackgroundVascular involvement is the most common cause of mortality and an important cause of disability in patients with Behçet’s syndrome (BS). Cyclophosphamide has been the treatment choice for severe vascular involvement, but high frequency o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::44f385ea29f9db4880eeb7d2fa9f6299
https://doi.org/10.1136/annrheumdis-2022-eular.3836

Zobrazit plný text záznamu

POS0814 DRUG RETENTION RATE, REASONS FOR DISCONTINUATION AND OUTCOME OF INFLIXIMAB USE IN BEHÇET SYNDROME

Autor: S. S. Taflan, Yesim Ozguler, Izzet Fresko, Zekayi Kutlubay, Gulen Hatemi, B. Tukek, Didar Ucar, Sinem Nihal Esatoglu, Ugur Uygunoglu, Melike Melikoglu, Halil Yazici, Vedat Hamuryudan, Aksel Siva, Emire Seyahi, Yilmaz Ozyazgan, Sebahattin Yurdakul

Publikováno v: Annals of the Rheumatic Diseases. 80:660-661

Background:Infliximab (IFX) plays a key role in the management of severe and refractory manifestations of Behçet syndrome (BS). However we had previously shown that its sustained use may be limited due to adverse events and lack of patient complianc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1ac686abba8e3df9d43d3e3aee8f08fb
https://doi.org/10.1136/annrheumdis-2021-eular.3262

Zobrazit plný text záznamu

AB0364 DO PATIENTS PARTICIPATING IN MEETINGS REPRESENT THE ACTUAL PATIENT POPULATION IN BEHÇET SYNDROME?

Autor: Yesim Ozguler, Sinem Nihal Esatoglu, S. S. Taflan, Melike Melikoglu, Gulen Hatemi, Berna Yurttas

Publikováno v: Annals of the Rheumatic Diseases. 80:1207.2-1207

Background:The importance of patient involvement in healthcare research is increasingly emphasized. Patients participate as research partners in designing studies and development of management recommendations, measurement tools and outcome measures.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bfd4225a33387872123ac16aa58c4094
https://doi.org/10.1136/annrheumdis-2021-eular.1643

Zobrazit plný text záznamu

AB0542 REACTIONS TO PNEUMOCOCCAL 13-VALENT VACCINE IN PATIENTS WITH BEHCET SYNDROME

Autor: N. Saltoglu, S. S. Taflan, Gulen Hatemi, Berna Yurttas

Publikováno v: Annals of the Rheumatic Diseases. 79:1567.2-1568

Background:The European League Against Rheumatism (EULAR) recommends pneumococcal 13-valent (PCV13) and 23-valent vaccines in patients with rheumatic diseases (1). Adverse reactions to 23-valent pneumococcal vaccine were previously reported in patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::78062b0efd54be31d49b1965893ca0e7
https://doi.org/10.1136/annrheumdis-2020-eular.5509

Zobrazit plný text záznamu

SAT0258 DRUG RETENTION RATE AND PROGNOSIS AFTER DISCONTINUATION OF INFLIXIMAB IN PATIENTS WITH BEHÇET SYNDROME

Autor: Halil Yazici, Sinem Nihal Esatoglu, S. S. Taflan, Melike Melikoglu, S. Yurdakul, Izzet Fresko, B. Tukek, Emire Seyahi, Vedat Hamuryudan, Yilmaz Ozyazgan, Didar Ucar, Gulen Hatemi, Aksel Siva, Ugur Uygunoglu

Publikováno v: Annals of the Rheumatic Diseases. 79:1071.2-1072

Background:Infliximab (IFX) has become an important treatment option for all manifestations of Behçet syndrome (BS). Adverse events, loss of efficacy, lack of patient compliance and cost may limit its sustained use in patients with BS.Objectives:We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e561da7e71727890844782e52af67d09
https://doi.org/10.1136/annrheumdis-2020-eular.3299

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání